Search
Tafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigational[L15307] It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.[L15292] … [L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling.
Fludrocortisone
go.drugbank.com/drugs/DB00687ApprovedInvestigationalFludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.
Lactose
go.drugbank.com/drugs/DB04465ApprovedInvestigationalWithdrawnA disaccharide of glucose and galactose in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.
Categories: Compounds used in a research, industrial, or household settingDrospirenone
go.drugbank.com/drugs/DB01395ApprovedInvestigationalDrospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. … [L7973] Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.
Mixtures: ETINILESTRADIOLO E DROSPIRENONE DOC, ETINILESTRADIOLO E DROSPIRENONE DOCGENSynonyms: 6β,7β;15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactoneNaxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigational[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely … Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.
Plecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalIt should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age … Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).
Peginterferon alfa-2a
go.drugbank.com/drugs/DB00008ApprovedInvestigationalIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) no longer recommend Peginterferon alfa … Approved in 2002 by the FDA, Pegasys is indicated for the treatment of HCV with [DB00811] or other antiviral drugs [FDA Label].
Categories: Compounds used in a research, industrial, or household settingDatopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … Datopotamab deruxtecan is an antibody-drug conjugate comprising a Trop-2-directed monoclonal antibody (datopotamab) and a DNA topoisomerase-I inhibitor, DDx.
Silver sulfadiazine
go.drugbank.com/drugs/DB05245ApprovedInvestigationalVet approvedSilver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.
Pomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.